Dammes, Niels
Goldsmith, Meir
Ramishetti, Srinivas
Dearling, Jason L. J.
Veiga, Nuphar
Packard, Alan B. http://orcid.org/0000-0003-0906-1021
Peer, Dan http://orcid.org/0000-0001-8238-0673
Article History
Received: 27 January 2020
Accepted: 7 May 2021
First Online: 17 June 2021
Competing interests
: D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee) or conducts sponsored research at TAU for the following entities: Alnylam Pharmaceuticals Inc. Arix Biosciences Inc., ART Biosciences, BioNtech RNA pharmaceuticals; Centricus, Diagnostear Ltd., EPM Inc., Earli Inc., lmpetis Biosciences, Kernal Biologics, GPCR Inc., Medison Pharma Ltd., Newphase Ltd, NLC Pharma Ltd., Nanocell Therapeutics, NanoGhosts Ltd., Precision Nanosystems Inc., Paul Hastings Inc., Regulon, Roche, SciCann, Shire Inc., VLX Ventures, TATA Cooperation, Teva Pharmaceuticals Inc., Wize Pharma Ltd. All other authors declare no competing financial interests. None of them relates to this work. The rest of the authors declare no financial interests.